CellCentric
CellCentric is a clinical-stage biotechnology company developing inobrodib, a first-in-class oral p300/CBP bromodomain inhibitor, for treating relapsed/refractory multiple myeloma and other cancers.
- Company typePrivate
- Founded2004
- HeadquartersCambridge, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What CellCentric does
CellCentric is a clinical-stage biotechnology company founded in 2003/2004 as a University of Cambridge spinout by Professor Azim Surani, headquartered in Cambridge, UK with additional operations in Manchester, UK and Burlington, MA (US office opened April 2025). The company is singularly focused on developing inobrodib (formerly CCS1477), a first-in-class oral small molecule inhibitor of p300/CBP bromodomains. Inobrodib binds selectively to the bromodomain of p300/CBP and displaces these transcription co-activators from super-enhancer sites, reducing expression of cancer-driving genes including MYC and IRF4, while leaving similar pockets on other proteins unaffected. The molecule has been evaluated in over 450 patients across multiple tumor types as monotherapy and in combination with standard-of-care agents.
The company's lead clinical focus is relapsed/refractory multiple myeloma (RRMM), with the all-oral InoPd regimen (inobrodib + pomalidomide + dexamethasone) positioned as the primary registration pathway. CellCentric has received FDA Fast Track and Orphan Drug designations for inobrodib in multiple myeloma and initiated the pivotal DOMMINO-1 Phase 2 trial in March 2026, with the global Phase 3 DOMMINO-2 trial planned for H2 2026. Secondary indications under investigation include metastatic castration-resistant prostate cancer, AML, lymphomas, and tumors with p300/CBP mutations.
CellCentric is pre-revenue with no commercial product sales. Its business model is a clinical-stage drug development approach, generating value through advancing inobrodib toward regulatory approval and eventual commercialization or partnership-driven monetization. Revenue mechanics are not yet established; pricing has not been disclosed. Go-to-market preparation is underway, evidenced by US office expansion and CEO statements regarding potential IPO timing with cash runway extending through 2029. The company has raised over $220 million in cumulative funding across multiple rounds, with the May 2026 $220M Series D (the largest private biotech financing in Europe for 2026) led by Venrock Healthcare Capital Partners.
CellCentric firmographics
Firmographics- Name
- CellCentric
- Legal name
- CellCentric Limited
- Website
- https://cellcentric.com
- Company type
- Private
- Founded year
- 2004
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- CellCentric is a clinical-stage biotechnology company developing inobrodib, a first-in-class oral p300/CBP bromodomain inhibitor, for treating relapsed/refractory multiple myeloma and other cancers.
- Ownership category
- akta.pro rank
CellCentric industry classification
Industry- Product category
- Oncology Pharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches) (HLAAACAF)
- akta.pro secondary industries
- mRNA Therapeutics (vaccines, protein replacement, immuno-oncology) (HLAAADAA), Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)
Keywords
Where CellCentric is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United Kingdom
- HQ region
- Europe
Offices3 records
Markets served
CellCentric business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Drug Commercialization: CellCentric is a clinical-stage biotech with no current revenue. The company plans to commercialize inobrodib for multiple myeloma and other cancer indications following successful clinical trials and regulatory approval. CEO Will West indicated an IPO is possible next year with cash runway extending through 2029.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
CellCentric product offering
Product offeringCore offering
CellCentric develops inobrodib, an oral, first-in-class small molecule inhibitor of p300/CBP bromodomains, for the treatment of multiple myeloma and other cancers. The drug binds to the bromodomain of p300/CBP, displacing these transcription co-activators from super-enhancer sites to reduce expression of cancer-driving genes such as MYC and IRF4, and is being advanced through clinical trials as monotherapy and in combination with standard of care agents.
Product overview
CellCentric is a clinical-stage biopharmaceutical company developing a single core product, inobrodib (formerly known as CCS1477), an oral first-in-class small molecule p300/CBP inhibitor for treating multiple myeloma and other cancers. The company operates as a drug development company advancing this one lead therapeutic candidate through clinical trials, with a focus on relapsed/refractory multiple myeloma. Inobrodib is being evaluated both as monotherapy and in combination with standard of care agents (pomalidomide and dexamethasone), with the all-oral combination regimen (InoPd) representing the primary development path toward registration.
Differentiator
Problem solved
Functional benefit
Products and services
- Inobrodib (CCS1477) Inobrodib is a first-in-class oral small molecule inhibitor of p300/CBP bromodomains, developed for the treatment of multiple myeloma and other cancers. It binds to the bromodomain of p300/CBP, displacing these transcription co-activators from super-enhancer sites to reduce expression of cancer-driving genes including MYC and IRF4. It is being evaluated both as monotherapy and in combination with standard of care agents (pomalidomide and dexamethasone).
Quantifiable outcome
- 69% objective response rate at 20mg dose in heavily pretreated RRMM patients
- +2 more outcomes
Companies that use CellCentric
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles2 records
CellCentric technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
CellCentric partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered minor and core.
- Columbia University (Prof. Laura Pasqualucci)minorAgreement to explore relevance of CCS1477 in treating haematological cancers. Prof. Pasqualucci originally identified p300/CBP as common target mutations in DLBCL and follicular lymphoma.
- The Christie NHS Foundation TrustcoreKey clinical trial site for haematological malignancies program. Prof. Tim Somervaille serves as Chief Investigator of the Phase 1/2 haematological malignancy study.
- Royal Marsden NHS Foundation TrustcoreInitial clinical trial site for prostate cancer studies. Prof. Johann de Bono, Regius Professor of Cancer Research at ICR and Royal Marsden, serves as lead clinical Principal Investigator.
Scale indicators9 records
Recent moves1 record
Expansion highlights5 records
CellCentric competitors and assessment
Company assessmentDirect peers
- Foghorn Therapeutics: Clinical-stage oncology biotech developing chromatin remodeling / BRG1-BRM inhibitors and other epigenetic cancer therapies. Highly comparable to CellCentric as a small-cap, single-platform epigenetic drug developer with a similar capital and clinical development profile.
- Karyopharm Therapeutics: Commercial and clinical-stage company developing selinexor (XPO1 inhibitor) for relapsed/refractory multiple myeloma. Directly comparable as the most established late-line oral MM competitor with similar patient population and clinical positioning.
- Prelude Therapeutics: Clinical-stage small molecule oncology company developing targeted therapies including PRT3789 (SMARCA2 degrader) and other epigenetic targets. Similar profile as a clinical-stage, single-platform oncology biotech focused on chromatin biology.
- Syndax Pharmaceuticals: Clinical-stage cancer therapeutics company developing epigenetic and immune-targeted therapies including revumenib (menin inhibitor) for AML. Comparable profile as a clinical-stage developer of mechanism-driven cancer therapies with FDA-approved product in recent launch.
- Arvinas: Clinical-stage biotechnology company developing targeted protein degradation (PROTAC) therapies for cancer. Similar business profile as a clinical-stage single-platform oncology biotech with novel mechanism of action and similar capital intensity.
- Monte Rosa Therapeutics: Clinical-stage oncology company developing molecular glue degraders for cancer and other diseases. Highly comparable as a clinical-stage single-platform biotech with novel mechanism of action targeting previously undruggable proteins.
Broad incumbents
- Bristol-Myers Squibb: Major multiple myeloma franchise holder with Revlimid, Pomalyst, and Empliciti, plus broad oncology portfolio. Comparable as the established leader in the MM treatment paradigm where CellCentric's inobrodib aims to compete in late-line settings.
- Johnson & Johnson: Holds the dominant MM franchise with Darzalex (anti-CD38) and Carvykti (BCMA CAR-T). Directly relevant incumbent whose marketed and pipeline MM therapies define the standard of care against which inobrodib must differentiate.
- Pfizer: CellCentric's strategic investor and SAB partner, also holder of Elrexfio (BCMA bispecific) and broader oncology portfolio. Comparable as a potential strategic acquirer and incumbent competitor in the MM space.
- Amgen: Holds Imdelltra (talquetamab) and other MM therapies including Blincyto franchise extension. Comparable broad incumbent with late-line MM therapies competing for the same patient population that inobrodib targets.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
CellCentric social profiles
Digital presenceCellCentric compliance and trust
Trust signalCompliance2 records
CellCentric financial estimates
Financial estimateRevenue estimate
Valuation estimate
CellCentric leadership team
Management profileNumber of profiles
Profiles19 records
CellCentric funding detail
Funding detailFunding overview
Funding rounds20 records
Investors22 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CellCentric M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CellCentric
What does CellCentric do?
CellCentric develops inobrodib, an oral, first-in-class small molecule inhibitor of p300/CBP bromodomains, for the treatment of multiple myeloma and other cancers. The drug binds to the bromodomain of p300/CBP, displacing these transcription co-activators from super-enhancer sites to reduce expression of cancer-driving genes such as MYC and IRF4, and is being advanced through clinical trials as monotherapy and in combination with standard of care agents.
Is CellCentric a public or private company?
CellCentric is a private company. It is classified as venture growth investor backed and is currently operating.
When was CellCentric founded?
CellCentric was founded in 2004. It employs 11 to 50 people.
Where is CellCentric based?
CellCentric is headquartered in Cambridge, United Kingdom, in the Europe region.
How does CellCentric make money?
One revenue line is on record: drug Commercialization.
Who are CellCentric's main competitors?
Direct peers on record are Foghorn Therapeutics, Karyopharm Therapeutics, Prelude Therapeutics, Syndax Pharmaceuticals, Arvinas and Monte Rosa Therapeutics. Broad incumbents are Bristol-Myers Squibb, Johnson & Johnson, Pfizer and Amgen.
Does CellCentric have an API?
No public API is recorded for CellCentric.
What industry is CellCentric in?
CellCentric's product category is Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAAACAF, Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches), with a secondary code of HLAAADAA, mRNA Therapeutics (vaccines, protein replacement, immuno-oncology). Its NAICS code is 325414 and its SIC code is 2836.